New Microarray technology to check bird 'flu

USA - A new technology, named glycan microarray, can identify pathogens in a few hours and give advance warning of the ability of a virus to infect humans.

This could prove vital in efforts to control the spread of bird ‘flu, say its inventors, who work on the Consortium for Functional Glycomics (CFG), a project of the National Institute of Health’s National Institute of General Medical Sciences. CFG members work at the Scripps Research Institute, in cooperation with Mount Sinai School of Medicine and the Armed Forces Institute of Pathology, have now offered this new technology free to virus researchers.

Generally, thousands of DNA samples can be deposited in microarrays. However, for many pathogens it is the carbohydrates on the surface of most human or bird cells that provide a binding site, and once bound, a virus can then penetrate the host cell, which causes infections. The CFG was established to ascertain what carbohydrates coat which cells, and to catalogue their vulnerability to infections from various pathogens. Thus, in their new microarray, the researchers spread glycans (carbohydrate) molecules across the whole array. ‘Our technology allows hundreds of different varieties to be put on a single glycan array,’ explained Jeremy Berg, Director of the National Institute of General Medical Sciences. ‘There’s a universe of carbohydrates on the surface of cells. Our technology was not developed specifically for influenza. It is a very broad research tool.’
However, if an influenza virus, for example, is introduced, the hemagglutinin (HA) - glycoprotein on its surface - binds to the surface carbohydrates of a host cell and, using a tagged antibody, the technology could recognize the particular carbohydrate, from human or bird cell, to which the hemagglutinin has bound.

01.05.2006

More on the subject:
Read all latest stories

Related articles

Photo

News • Urine-based diagnostics

New prostate cancer test to help avoid unnecessary biopsies

US researchers have developed and validated a new urine-based test for prostate cancer, which was shown to meaningfully reduce unnecessary prostate biopsies while providing highly accurate detection.

Photo

News • Presented at ESCMID Global

Immunoassay analyzer extends menu with new hepatitis assays

Beckman Coulter Diagnostics announced ahead of the ESCMID Global congress (formerly ECCMID) that it has extended the menu of DxI 9000 Immunoassay Analyzer* assays.

Photo

News • Research on syndrome correlation

Finding the link between Guillain-Barré and Takotsubo

Takotsubo cardiomyopathy (‘broken heart syndrome’) is a known complication of Guillain-Barré, but not much is known about the association between the two. New research aims to change this.

Related products

Subscribe to Newsletter